Herpesvirus encephalitis

Encephalitis: Diagnosis and Treatment

Volumn , Issue , 2007, Pages 167-194

  King, Nicholas L ^a   Roos, Karen L ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056943222     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (142)

1. Glaser Ca GS, Schnurr D, et al. In search of encephalitis etiologies: Diagnostic challenges in the california encephalitis project, 1998-2000. Clin Infect Dis 2003; 36:731-42.
2. Fodor PA, Levin MJ, Weinberg A, et al. Atypical herpes simplex virus encephalitis diagnosed by PCR amplification of viral DNA from CSF [see comment]. Neurology 1998; 51(2):554-9.
3. Roos KL. Encephalitis. In: Roos KL. Principles of Neurologic Infectious Diseases. The McGraw-Hill Companies, Inc. New York. 2005.
4. Whitley RJ. Viral encephalitis. N Engl J Med 1990; 323(4):242-50.
5. Levitz, R.E. Herpes simplex encephalitis: A review. Heart Lung 1998; 27(3): 209-12.
6. http://www.ncbi.nlm.nih.gov/ICTVdb/Ictv/fs_herpe.htm (accessed April 2005).
7. Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1998; 1(8594):1065-7.
8. Agut H, Dupin N, Aubin JT, et al. Human herpesvirus 8. Annales de Medicine Interne 1997; 148(5):385-9.
9. Tanaka K, Kondo T, Torigoe S, et al. Human herpesvirus 7: Another causal agent for Roseola (Exanthem subitum). J Pediatrics 1994; 125(1) 1-5.
10. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56:29-44.
11. http://pathmicro.med.sc.edu/virol/herpes.htm (accessed April 2005).
12. Whitley RJ, Kimberlin, D.W. Roizman, B. Herpes simplex viruses. Clin Infect Dis 1998; 26(3):541-53.
13. Lang A, Nikolich-Zugich J. Development and migration of protective CD8 plus T cells into the nervous system following ocular herpes simplex virus-1 infection. J Immunol 2005; 174(5):2919-25.
14. Anglen CS, Truckenmiller ME, Schell TD, et al. The dual role of CD8plus T lymphocytes in the development of stress-induced herpes simplex encephalitis. J Neuroimmunology 2003; 140(1-2):13-27.
15. Beghi E, Nicolosi A, Kurland LT, Mulder DW, Hauser WA, Shuster L. Encephalitis and aseptic meningitis, Olmsted county, Minnesota, 1950-1981: I. Epidemiology. Ann Neurol 1984; 16(3):283-94.
16. Domingues R, Tsanaclis A, Pannuti C, et al. Evaluation of the range of clinical presentations of herpes simplex encephalitis by using polymerase chain reaction assay of cerebrospinal fluid samples. Clin Infect Dis 1997; 25:86-91.
17. Skoldenberg B. Herpes simplex encephalitis. Scand J Infect Dis Suppl 1991; 80:40-6.
18. Koskiniemi M, Piiparinen H, Mannonen L, et al. Herpes encephalitis is a disease of middle aged and elderly people: Polymerase chain reaction for detection of herpes simplex virus in the CSF of 516 patients with encephalitis. J Neurol Neurosurg Psychiatry 1996; 60(2):174-8.
19. Whitley R, Soong S-J, Linneman C. Herpes simplex encephalitis. Clinical assessment. J Am Med Assoc 1982; 247:317-20.
20. Ward PL, Roizman B. Herpes simplex genes: The blueprint of a successful human pathogen. Trends in Genetics 1994; 10(8):267-74.
21. Domingues R, Fink M, Tsanaclis A, et al. Diagnosis of herpes simplex encephalitis by magnetic resonance imaging and polymerase chain reaction assay of cerebrospinal fluid. J Neurol Sci 1998; 157:148-53.
22. Domingues RB, Lakeman FD, Mayo MS, et al. Application of competitive PCR to cerebrospinal fluid samples from patients with herpes simplex encephalitis. J Clin Microbiol 1998; 36(8):2229-34.
23. Raschilas F, Wolff M, Delatour F, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: Results of a multicenter study. Clin Infect Dis 2002; 35:254-60.
24. Skoldenberg B, Forsgren M, Alestig K, et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive swedish patients [see comment]. Lancet 1984; 2(8405):707-11.
25. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986; 314(3):144-9.
26. Simko J, Caliendo A, Hogle K, et al. Differences in laboratory findings for cerebrospinal fluid specimens obtained from patients with meningitis or encephalitis due to herpes simplex virus (HSV) documented by detection of HSV DNA. Clin Infect Dis 2002; 35:414-19.
27. Al-Shekhlee A, Kocharian N, Suarez JJ. Re-evaluating the diagnostic methods in herpes simplex encephalitis [see comment]. Herpes 2006; 13(1):17-19.
28. Misra UK, Kalita J. Neurophysiological studies in herpes simplex encephalitis. Electromyogr Clin Neurophysiol 1998; 38(3):177-82.
29. Smith J, Westmoreland B, Ragan T, et al. A distinctive eeg profile in herpes simplex encephalitis. Mayo Clin Proc 1975; 50(8): 469-74.
30. Tyler KL. Update on herpes simplex encephalitis. Rev Neurol Dis 2004; 1(4): 169-78.
31. Lakeman FD, Whitley RJ. Diagnosis of herpes simplex encephalitis: Application of polymerase chain reaction to cerebrospinal fluid from brainbiopsied patients and correlation with disease. National institute of allergy and infectious diseases collaborative antiviral study group [see comment]. J Infect Dis 1995; 171(4):857-63.
32. Tebas P, Nease RF, Storch GA. Use of the polymerase chain reaction in the diagnosis of herpes simplex encephalitis: A decision analysis model. Am J Med 1998; 105(4):287-95.
33. Aurelius E, Johansson B, Skoldenberg B, et al. Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet 1991; 337:189-92.
34. Baringer JR, Pisani P. Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. Ann Neurol 1994; 36:823.
35. De Tiege X, Heron B, Lebon P, et al. Limits of early diagnosis of herpes simplex encephalitis in children: A retrospective study of 38 cases. Clin Infect Dis 2003; 36(10):1335-9.
36. Weil AA, Glaser CA, Amad Z, et al. Patients with suspected herpes simplex encephalitis: Rethinking an initial negative polymerase chain reaction result. Clin Infect Dis 2002; 34(8):1154-7.
37. Revello MG, Baldanti F, Sarasini A, et al. Quantitation of herpes simplex virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis by the polymerase chain reaction. Clin Diagn Virol 1997; 7(3):183-91.
38. Kahlon J, Chatterjee S, Lakeman FD, et al. Detection of antibodies to herpes simplex virus in the cerebrospinal fluid of patients with herpes simplex encephalitis. J Infect Dis 1987; 155(1):38-44.
39. Mcgrath N, Anderson NE, Croxson MC, et al. Herpes simplex encephalitis treated with acyclovir: Diagnosis and long term outcome. J Neurol Neurosurg Psychiatry. 1997; 63(3):321-6.
40. Meyding-Lamade UK, Oberlinner C, Rau PR, et al. Experimental herpes simplex virus encephalitis: A combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities. J Neurovirol 2003; 9(1):118-25.
41. Nakano A, Yamasaki R, Miyazaki S, et al. Beneficial effect of steroid pulse therapy on acute viral encephalitis. Eur Neurol 2003; 50(4):225-9.
42. Dalai SK, Pesnicak L, Miller GF, et al. Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice. J Neurovirol 2002; 8(1):35-44.
43. Geiger KD, Nash TC, Sawyer S, et al. Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology 1997; 238(2):189-97.
44. Morfin, F. and Thouvenot, D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26(1):29-37.
45. Chibo D, Mijch A, Doherty R, et al. Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient. J Clin Virol 2002; 25(2):165-70.
46. Blot N, Schneider P, Young P, et al. Treatment of an acyclovir and foscarnetresistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant 2000; 26:903-5.
47. Bryant P, Sasadeusz J, Carapetis J, et al. Successful treatment of foscarnetresistant herpes simplex stomatitis with intravenous cidofovir in a child. Pediatr Infect Dis J 2001; 20(11):1083-6.
48. Lopresti AE, Levine JF, Munk GB, et al. Successful treatment of an acyclovirand foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. Clin Infect Dis 1998; 26:512-3.
49. Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 1994; 18:570-8.
50. Saijo M, Suzutani T, Morikawa S, et al. Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain. Antimicrob Agents Chemother 2005; 49(2):606-11.
51. Wyles DL, Patel A, Madinger N, et al. Development of herpes simplex virus disease in patients who are receiving cidofovir. Clinical Infectious Disease 2005; 41:676-80.
52. Abendroth A, Arvin AM. Immune evasion as a pathogenic mechanism of varicella zoster virus. Seminars in Immunology 2001; 13:27-39.
53. Gilden DH, Kleinschmidt-Demasters BK, Laguardia JJ, et al. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000; 342(9) 635-45.
54. Etzioni A, Eidenschenk C, Katz R, et al. Fatal varicella associated with selective natural killer cell deficiency. J Pediatrics 2005; 146:423-5.
55. Hambleton, S. Chickenpox. Curr Opin Infect Dis 2005; 18:235-40.
56. Kleinschmidt-Demasters BK, Amlie-Lefond C, Gilden DH. The patterns of varicella zoster virus encephalitis. Human Pathol 1996; 27(9):927-38.
57. Meyer PA, Seward JF, Jumaan AO, et al. Varicella mortality: Trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 2000; 182: 383-90.
58. Martin JA, Hamilton BE, Sutton PD, et al. Births: Final data for 2002. National Vital Statistics Reports 2003; 52(10):30.
59. Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. J Am Med Assoc 2005; 294(7):797-802.
60. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352:450-8.
61. Gnann JW. Varicella-zoster virus: Atypical presentations and unusual complications. J Infect Dis 2002; 186(Suppl 1):S91-98.
62. Hunter W. Case of varicella complicated with convulsions. Lancet 1875; 1:45.
63. Goddard R. The reawakening of a sleeping little giant. Emerg Med J 2005; 22(5):384-6.
64. Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia: If early treatment fails, patients should be referred to pain clinics. Br Med J 2000; 321(7264):778-9.
65. Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2(7892):1288-90.
66. Prevention CFDCA. National, state, and urban area vaccination coverage among children aged 19-35 months-United States, 2003. Morb Mortal Wkly Rep 2004; 53(29):658-61.
67. Vazquez M, Larussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine [see comment]. JAMA 2004; 291(7):851-5.
68. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination [see comment]. N Engl J Med 2002; 347(24):1909-15.
69. Prevention CFDCA. Decline in annual incidence of varicella-selected states, 1990-2001. Morb Mortal Wkly Rep 2003; 52(37):884-5.
70. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287(5):606-11.
71. Jumaan AO, Onchee Y, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191:2002-7.
72. Holodniy M. Prevention of shingles by varicella zoster virus vaccination. Expert Rev Vaccines 2006; 5(4):431-43.
73. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults [see comment]. N Engl J Med 2005; 352(22):2271-84.
74. Jemsek J, Greenberg SB, Taber L, et al. Herpes zoster-associated encephalitis: Clinicopathologic report of 12 cases and review of the literature. Medicine 1983; 62(2):81-97.
75. Weaver S, Rosenblum MK, Deangelis LM. Herpes varicella zoster encephalitis in immunocompromised patients. Neurology 1999; 52(1):193-5.
76. Gilden DH, Cohrs RJ, Mahalingam R. VZV vasculopathy and postherpetic neuralgia: Progress and perspective on antiviral therapy. Neurology 2005; 64(1): 21-5.
77. Corral I, Quereda C, Antela A, et al. Neurological complications of varicellazoster virus in human immunodeficiency virus-infected patients: Changes in prevalence and diagnostic utility of polymerase chain reaction in cerebrospinal fluid. J Neurovirol 2003; 9(1):129-35.
78. Debiasi R, Solbrig M, Tyler KL. Neurology in clinical practice Fourth Bradley W, Daroff R, Fenichel G. and Jankovic J. Elsevier Inc. Philadelphia 2004; 1515-1543.
79. Debiasi R, Tyler K. Molecular methods for diagnosis of viral encephalitis. Clin Microbiol Rev 2004; 17(4):903-25.
80. Koskiniemi M, Piiparinen H, Rantalaiho T, et al. Acute central nervous system complications in varicella zoster virus infections. J Clin Virol 2002; 25(3):293-301.
81. Maslen HL, Hughes D, Hursthouse M, et al. 6-Azapyrimidine-2'-deoxy-4'-thionucleosides: Antiviral agents against tk+ and tk-HSV and VZV strains. J Med Chem 2004; 47(22):5482-91.
82. Bale JF, Jr. Human cytomegalovirus infection and disorders of the nervous system. Arch Neurol 1984; 41(3):310-20.
83. Sinclair, J. and Sissons, P. Latent and persistent infections of monocytes and macrophages. Intervirology 1996; 39(5-6):293-301.
84. Mendelson M, Monard S, Sissons P, et al. Detection of endogenous human cytomegalovirus in CD34 plus bone marrow progenitors. J Gen Virol 1996; 77 Pt 12:3099-102.
85. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci USA 1998; 95(7): 3937-42.
86. Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci USA 1994; 91(25):11879-83.
87. Arribas JR, Storch GA, Clifford DB, et al. Cytomegalovirus encephalitis. Ann Intern Med 1996; 125(7):577-87.
88. Morgello S, Cho ES, Nielsen S, et al. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: An autopsy study of 30 cases and a review of the literature. Human Pathol 1987; 18(3):289-97.
89. Cinque P, Cleator GM, Weber T, et al. Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. J Neurovirol 1998; 4:120-32.
90. Roos KL. Encephalitis. Neurol Clin 1999; 17(4):813-33.
91. Griffiths PD, Walter S. Cytomegalovirus. Curr Opin Infect Dis 2005; 18(3): 241-5.
92. Gilbert C, Boivin, G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49(3):873-83.
93. Chaudhuri A, Kennedy PG. Diagnosis and treatment of viral encephalitis. Postgrad Med J 2002; 78(924):575-83.
94. Studahl M, Ricksten A, Sandberg T, et al. Cytomegalovirus infection of the cns in non-compromised patients. Acta Neurol Scand 1994; 89(6):451-7.
95. Arribas JR, Clifford DB, Fichtenbaum CJ, et al. Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J Infect Dis 1995; 172(2):527-31.
96. Fletcher C, Sawchuk R, Chinnock B, et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986; 40(3):281-6.
97. Smee DF, Martin JC, Verheyden JP, et al. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother 1983; 23(5):676-82.
98. Jung D, Dorr, A. Single-dose pharmacokinetics of valganciclovir in HIV-and CMV-seropositive subjects. J Clin Pharmacol 1999; 39(8):800-4.
99. Brown F, Banken L, Saywell K, et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV-and CMV-seropositive volunteers. Clin Pharmacokinet 1999; 37(2):167-76.
100. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44(10):2811-15.
101. Katlama C, Dohin E, Caumes E, et al. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: Comparison of twice-daily and threetimes-daily regimens. J Acquir Immune Defic Syndr 1992; 5(Suppl 1): S18-24.
102. Anonymous Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The cytomegalovirus retreatment trial. The studies of ocular complications of AIDS research group in collaboration with the AIDS clinical trials group. Arch Ophthalmol 1996; 114(1):23-33.
103. Manischewitz JF, Quinnan GV, Jr, Lane HC, et al. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1990; 34(2):373-5.
104. Mattes FM, Hainsworth EG, Geretti AM, et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004; 189(8):1355-61.
105. Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum [see comment]. Lancet 1988; 1 (8594):1065-7.
106. Levy JA. Three new human herpesviruses (HHV6, 7, and 8). Lancet 1997; 349: 558-62.
107. Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986; 234(4776):596-601.
108. Ward KN, Gray JJ, Fotheringham MW, et al. IgG antibodies to human herpesvirus-6 in young children: Changes in avidity of antibody correlate with time after infection. J Med Virol 1993; 39(2):131-8.
109. Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994; 331(7):432-8.
110. Yoshikawa T, Suga S, Asano Y, et al. Distribution of antibodies to a causative agent of Exanthem subitum (human herpesvirus-6) in healthy individuals. Pediatrics 1989; 84(4):675-7.
111. Ward KN, Andrews NJ, Verity CM, et al. Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland. Arch Dis Child 2005; 90(6):619-23.
112. Luppi M, Barozzi P, Maiorana A, et al. Human herpesvirus 6 infection in normal human brain tissue. J Infect Dis 1994; 169(4):943-4.
113. Takahashi K, Sonoda S, Higashi K, et al. Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus. J Virol 1989; 63(7): 3161-3.
114. Levy JA, Ferro F, Lennette ET, et al. Characterization of a new strain of HHV-6 (HHV-6SF) recovered from the saliva of an HIV-infected individual. Virology 1990; 178(1):113-21.
115. Mccullers JA, Lakeman FD, Whitley RJ. Human herpesvirus 6 is associated with focal encephalitis. Clin Infect Dis 1995; 21(3):571-6.
116. Suga S, Yoshikawa T, Asano Y, et al. Clinical and virological analyses of 21 infants with Exanthem subitum (Roseola infantum) and central nervous system complications. Ann Neurol 1993; 33(6):597-603.
117. Kamei A, Ichinohe S, Onuma R, et al. Acute disseminated demyelination due to primary human herpesvirus-6 infection. Eur J Pediatr 1997; 156(9): 709-12.
118. Ward KN. Human herpesviruses-6 and -7 infections. Curr Opin Infect Dis 2005; 18(3):247-52.
119. Yoshihara S, Kato R, Inoue T, et al. Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. Transplantation 2004; 77(6):835-8.
120. Singh N, Paterson DL. Encephalitis caused by human herpesvirus-6 in transplant recipients: Relevance of a novel neurotropic virus. Transplantation 2000; 69(12):2474-9.
121. Zerr DM, Gupta D, Huang ML, et al. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34(3):309-17.
122. Cole PD, Stiles J, Boulad F, et al. Successful treatment of human herpesvirus 6 encephalitis in a bone marrow transplant recipient. Clin Infect Dis 1998; 27(3): 653-4.
123. Frenkel N, Schirmer EC, Wyatt LS, et al. Isolation of a new herpesvirus from human Cd4 plus T cells. Proc Natl Acad Sci USA 1990; 87:748-52.
124. Ablashi DV, Berneman ZN, Kramarsky B, et al. Human herpesvirus-7 (HHV-7). In Vivo 1994; 8(4):549-54.
125. Wyatt LS, Frenkel N. Human herpesvirus 7 is a constitutive inhabitant of adult human saliva. J Virol 1992; 66(5):3206-9.
126. Van Den Berg JSP, Van Zeijl JH, Rotteveel JJ, et al. Neuroinvasion by human herpesvirus type 7 in a case of Exanthem subitum with severe neurologic manifestations. Neurology 1999; 52(5):1077-9.
127. Wyatt LS, Rodriguez WJ, Balachandran N, et al. Human herpesvirus 7: Antigenic properties and prevalence in children and adults. J Virol 1991; 65(11):6260-5.
128. Ward KN, Kalima P, Macleod KM, et al. Neuroinvasion during delayed primary hhv-7 infection in an immunocompetent adult with encephalitis and flaccid paralysis. J Med Virol 2002; 67(4):538-41.
129. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343(7):481-92.
130. Jenson HB. Acute complications of Epstein-Barr virus infectious mononucleosis. Curr Opin Pediatr 2000; 12(3):263-8.
131. Henke CE, Kurland LT, Elveback LR. Infectious mononucleosis in Rochester, Minnesota, 1950 through 1969. Am J Epidemiol 1973; 98(6):483-90.
132. Straus SE, Cohen JI, Tosato G, et al. NIH conference. Epstein-Barr virus infections: Biology, pathogenesis, and management. Ann Intern Med 1993; 118(1):45-58.
133. Husler M, Ramaekers VT, Doenges M, et al. Neurological complications of acute and persistent Epstein-Barr virus infection in paediatric patients. J Med Virol 2002; 68:253-63.
134. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Asts/Astp Ebv-Ptld task force and the Mayo clinic organized international consensus development meeting. Transplantation 1999; 68(10):1517-25.
135. Donovan WD, Zimmerman RD. Case report. MRI findings of severe Epstein-Barr virus encephalomyelitis. J Comput Assist Tomogr 1996; 20(6): 1027-9.
136. Cecil KM, Jones BV, Williams S, et al. CT, MRI and MRS of Epstein-Barr virus infection: Case report. Neuroradiology 2000; 42(8):619-22.
137. Domachowske JB, Cunningham CK, Cummings DL, et al. Acute manifestations and neurologic sequelae of Epstein-Barr virus encephalitis in children [see comment]. Pediatr Infect Dis J 1996; 15(10):871-5.
138. Studahl M, Hagberg L, Rekabdar E, et al. Herpesvirus DNA detection in cerebral spinal fluid: Differences in clinical presentation between alpha-, beta-, and gamma-herpesviruses. Scand J Infect Dis 2000; 32(3):237-48.
139. Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: A meta-analysis. Scand J Infect Dis 1999; 31(6):543-7.
140. Said JW, Tasaka T, De Vos S, et al. Kaposi’s sarcoma-associated herpesvirus/human herpesvirus type 8 encephalitis in HIV-positive and -negative individuals. Aids 1997; 11(9):1119-22.
141. Broccolo F, Iuliano R, Careddu AM, et al. Detection of lymphotropic herpesvirus DNA by polymerase chain reaction in cerebrospinal fluid of AIDS patients with neurological disease. Acta Virol 2000; 44(3):137-43.
142. Brink NS, Sharvell Y, Howard MR, et al. Detection of Epstein-Barr virus and kaposi’s sarcoma-associated herpesvirus DNA in CSF from persons infected with HIV who had neurological disease. J Neurol Neurosurg Psychiatry 1998; 65(2):191-5.